Enquiry/Quote
Diamorphine Hydrochloride bulk supplier for pharma manufacturers

Diamorphine Hydrochloride Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 5 mg/mL, 10 mg/mL

Reference Brands: Generic formulations marketed under different names

Category: Pain Management

Diamorphine Hydrochloride is available in Injection and strengths such as 5 mg/mL, 10 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Diamorphine Hydrochloride is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Diamorphine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Diamorphine, also known as diacetylmorphine or heroin, is a highly potent opioid derived from morphine, which is naturally found in the seed pods of the opium poppy plant. It acts by binding to mu-opioid receptors in the central nervous system, blocking pain signals and altering the body’s perception of pain. Historically, diamorphine was used medically to manage severe pain, including in surgical, trauma, and palliative care settings, due to its rapid and strong analgesic effects.

Because of its high potential for addiction and abuse, diamorphine is now tightly controlled and is illegal for general medical use in many countries, including the United States. It is classified as a controlled substance due to its risk of dependence, respiratory depression, and other serious side effects. Despite its medical origins, the non-medical use of diamorphine is associated with significant health risks, including overdose and long-term neurological and physiological consequences.

In medicine, diamorphine remains a critical example of an opioid with powerful pain-relieving properties, highlighting the importance of careful regulation, monitoring, and alternative therapies for pain management in modern clinical practice.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Diamorphine hydrochloride is used for the management of severe pain when other opioids are insufficient, particularly in palliative care, acute postoperative pain, or trauma pain settings. It may also be employed in selected specialty programs for opioid substitution therapy under strict medical supervision.

Diamorphine is a synthetic opioid derived from morphine. The pharmaceutical formulation contains diamorphine hydrochloride dissolved in a sterile aqueous solution suitable for parenteral (injectable) use.

In markets where it is licensed, diamorphine products are often simply labeled under the generic name (e.g., Di‑Morphine) rather than distinctive commercial brands due to controlled distribution. Available presentations vary by country and regulatory approval.

Diamorphine injectables are typically manufactured by licensed pharmaceutical suppliers that specialize in controlled opioids for hospital use. In Europe, this may include specialty manufacturers supplying hospital pharmacies under strict schedules. (Specific brand manufacturers are limited because of tight control on marketing authorizations.)

The generic name is diamorphine hydrochloride.

Where available, it is marketed as Di‑Morphine or under similar descriptors reflective of the active ingredient; distinctive consumer brand names are not typical because of controlled distribution.

Medical diamorphine products are manufactured in regulated facilities, commonly within Europe (UK/Netherlands/Germany) under strict Good Manufacturing Practices (GMP) for controlled substances and supplied to hospital pharmacies and national health systems.

Yes, Diamorphine Hydrochloride is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Diamorphine Hydrochloride is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Hyaluronic Acid

Strength:
20 mg/mL, 6 mL, 0.15%–0.3%

Form: Injection / Drop

Reference Brands: Synvisc (USA), Ostenil (EU)

View Details
Nefopam Hydrochloride

Strength:
30 mg, 20 mg/2 mL

Form: Tablet / Injection

Reference Brands: Acupan (UK),

View Details
Ziconotide Acetate

Strength:
25 mcg/mL

Form: Intrathecal solution

Reference Brands: Prialt (USA/EU)

View Details
Hydromorphone Tablet

Strength:
2mg, 4mg, 8mg / 1 mg/mL, 2 mg/mL, 4 mg/mL

Form: Tablets/ capsules/ Injectable / Oral Solution

Reference Brands: Dilaudid (USA), Exalgo, Palladone(EU/UK)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.